Literature DB >> 12823240

Serum levels of low molecular weight advanced glycation end products in diabetic subjects.

P S Sharp1, S Rainbow, S Mukherjee.   

Abstract

AIMS: One of the principal theories of the development of diabetic complications proposes that increased levels of advanced glycation end products (AGE) are formed in diabetes by prolonged exposure of proteins, lipids and nucleotides to glucose. Such AGEs may contribute to the development of diabetic complications by a number of mechanisms. Circulating AGEs can be detected in serum, and in the present study, we analysed the clinical correlates of circulating serum low molecular weight AGE (LMW-AGE).
METHODS: Serum LMW-AGE was measured in 106 non-diabetic and 499 diabetic subjects using fluorescence spectroscopy. Results were calibrated against an in-house AGE albumin preparation, and expressed as absolute fluorescence units (AFU).
RESULTS: Serum LMW-AGE values were significantly higher in diabetic than non-diabetic subjects [median 7.5 (range 0-595.5) vs. 5.3 (1.0-15.5) AFU, P<0.01]. In the normal subjects, there were significant correlations between serum LMW-AGE and age (r=0.42, P<0.01) and serum creatinine (r=0.39, P<0.01). In the diabetic patients, serum LMW-AGE correlated significantly with age (r=0.315, P<0.01), systolic blood pressure (r=0.141, P=0.002), serum creatinine (r=0.449, P<0.01) and urinary albumin/creatinine ratio (ACR) (r=0.265, P<0.01). There was no correlation between serum LMW-AGE and HbA1c. On regression analysis, with serum LMW-AGE as the dependent variable, serum creatinine emerged as the most significant factor (t=8.1, P<0.01), followed by age (t=4.0, P<0.01) and ACR (t=2.9, P=0.004). There was no significant difference in serum LMW-AGE between those with and without retinopathy or in those with vascular disease.
CONCLUSIONS: We conclude that circulating LMW-AGEs are increased in diabetic subjects. The major determinant appears to be renal dysfunction in the form of raised albumin/creatinine ratio or creatinine. There was no association with other markers of vascular disease or presence of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823240     DOI: 10.1046/j.1464-5491.2003.00973.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

1.  Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging.

Authors:  R D Semba; J Beck; K Sun; J M Egan; O D Carlson; R Varadhan; L Ferrucci
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

2.  Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro.

Authors:  Savita Bansal; Manushi Siddarth; Diwesh Chawla; Basu D Banerjee; S V Madhu; Ashok K Tripathi
Journal:  Mol Cell Biochem       Date:  2011-11-03       Impact factor: 3.396

3.  Serum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the Age, Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Richard D Semba; Mary Frances Cotch; Vilmundur Gudnason; Gudny Eiríksdottir; Tamara B Harris; Kai Sun; Ronald Klein; Fridbert Jonasson; Luigi Ferrucci; Debra A Schaumberg
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

Review 4.  Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Authors:  Kailash Prasad; Manish Mishra
Journal:  Int J Angiol       Date:  2017-02-03

5.  Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults.

Authors:  Richard D Semba; Kai Sun; Ann V Schwartz; Ravi Varadhan; Tamara B Harris; Suzanne Satterfield; Melissa Garcia; Luigi Ferrucci; Anne B Newman
Journal:  J Hypertens       Date:  2015-04       Impact factor: 4.844

Review 6.  Advanced glycation end products, oxidative stress and diabetic nephropathy.

Authors:  Sho-Ichi Yamagishi; Takanori Matsui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

7.  Use of human vascular tissue microarrays for measurement of advanced glycation endproducts.

Authors:  Marc K Halushka; Elizabeth Selvin; Jie Lu; Anne M Macgregor; Toby C Cornish
Journal:  J Histochem Cytochem       Date:  2009-02-16       Impact factor: 2.479

Review 8.  Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2014-03

9.  The Association of -429T>C and -374T>A Polymorphisms in the RAGE Gene with Polycystic Ovary Syndrome.

Authors:  Jung-Hyun Park; Lan Li; Jin-Woo Choi; Kwang-Hyun Baek
Journal:  Int J Med Sci       Date:  2016-06-01       Impact factor: 3.738

10.  Acute exposure to a precursor of advanced glycation end products induces a dual effect on the rat pancreatic islet function.

Authors:  Ghada Elmhiri; Luiz Felipe Barella; Didier Vieau; Sylvaine Camous; Paulo C F Mathias; Latifa Abdennebi-Najar
Journal:  Int J Endocrinol       Date:  2014-11-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.